Talaris Therapeutics, Inc.
NASDAQ:TALS
2.72 (USD) • At close October 19, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Talaris Therapeutics, Inc. |
Symbool | TALS |
Munteenheid | USD |
Prijs | 2.72 |
Beurswaarde | 116,444,832 |
Dividendpercentage | 55.58% |
52-weken bereik | 0.89 - 3.29 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Ms. Mary Kay Fenton |
Website | https://talaristx.com |
An error occurred while fetching data.
Over Talaris Therapeutics, Inc.
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)